The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Original Article

18F-FDG PET/CT Evaluation of Lymphoma with Renal Involvement: Comparison with Renal Carcinoma

Authors: Xiang-Hua Ye, MD, Long-Hua Chen, PhD, MD, Hu-Bing Wu, PhD, Jie Feng, MD, Wen-Lan Zhou, MD, Rui-Meng Yang, MD, Zhi-Bin Bu, MD, Yi Ding, MD, Jian Guan, PhD, MD, Quan-Shi Wang, PhD

Abstract

Objective: Lymphoma can arise at any anatomic site, but it is rare to find kidney involvement. The aim of this study was to assess the role of 18F-flourodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) in detecting lymphoma with renal involvement. Reports of such use of 18F-FDG PET/CT are limited.


Methods: Twelve lymphoma patients with renal involvement and 12 renal carcinoma patients were studied with 18F-FDG PET/CT. Intense 18F-FDG uptake, suggestive of positivity, was measured in mean standardized uptake values (standardized uptake values [SUV] mean).


Results: The results of PET/CT were validated by bone marrow, biopsy tissue and/or surgery.18F-FDG PET/CT detected lymphoma with renal involvement lesions or renal carcinoma lesions in at least one site in the 24 patients. 18F-FDG uptake by the lymphoma lesions was much higher than the 18F-FDG uptake by the renal clear cell carcinomas (SUV mean 6.37 ± 2.28 vs 2.58 ± 0.62), and similar to that of renal cell carcinoma and renal collecting duct carcinoma (SUV mean 6.37 ± 2.28 vs 6.27 ± 1.15). There were dissimilar morphological changes in the homologous CT. Differing from renal cancer, lymphoma in the spleen, uterus, and bone marrow can easily be diagnosed by 18F-FDG PET/CT.


Conclusion: The lesions of lymphoma with renal involvement, and especially those of primary renal lymphoma, are 18F-FDG avid. PET/CT appears to be useful in comparing these lesions with those of renal carcinoma, especially for primary renal lymphoma.


Key Points


* The present study demonstrated that 18F-FDG PET/CT is a useful tool for diagnosing lymphoma with renal involvement.


* 18F-FDG uptake of the lesions in lymphoma was much higher than the 18F-FDG uptake focusing on renal clear cell carcinoma (SUV mean 6.37 ± 2.28 vs 2.58 ± 0.62).


* 18F-FDG uptake of lymphoma lesions were similar to that of renal cell carcinoma and renal collecting duct carcinoma (SUV mean 6.37 ± 2.28 vs 6.27 ± 1.15), but there were dissimilar morphological changes in the homologous computed tomography scan.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Juweid ME, Stroobants S, Hoekstra OS, et al; Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571–578.
 
2. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
 
3. Allen-Auerbach M, de Vos S, Czernin J. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients. Radiol Clin North Am2008;46:199–211, vii.
 
4. Terasawa T, Nihashi T, Hotta T, et al. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review. J Nucl Med 2008;49:13–21.
 
5. Kaneta T, Hakamatsuka T, Yamada T, et al. FDG PET in solitary metastastic/secondary tumor of the kidney: a report of three cases and a review of the relevant literature. Ann Nucl Med 2006;20:79–82.
 
6. Hernandez-Maraver D, Hernandez-Navarro F, Gomez-Leon N, et al. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma. Br J Haematol 2006;135:293–302.
 
7. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003;101:3875–3876.
 
8. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood2007;110:3507–3516.
 
9. Kumar R, Nadig MR, Chauhan A. Positron emission tomography: clinical applications in oncology. Part 1. Expert Rev Anticancer Ther 2005;5:1079–1094.
 
10. Nyman R, Rhen S, Ericsson A, et al. An attempt to characterize malignant lymphoma in spleen, liver and lymph nodes with magnetic resonance imaging. Acta Radiol 1987;28:527–533.
 
11. Kugel V, Dekel Y, Konichezky M, et al. Unusual splenic metastasis from renal cell carcinoma. A case report and review of the literature. Pathol Res Pract 2003;199:739–743.
 
12. Munker R, Stengel A, Stäbler A, et al. Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkin's disease. Verification by laparotomy in 100 cases. Cancer 1995;76:1460–1466.
 
13. Even-Sapir E, Lievshitz G, Perry C, et al. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease. Radiol Clin North Am 2007;45:697–709, vii.
 
14. Rueffer U, Sieber M, Stemberg M, et al; German Hodgkin's Lymphoma Study Group (GHSG). Spleen involvement in Hodgkin's lymphoma: assessment and risk profile. Ann Hematol 2003;82:390–396.
 
15. Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin 2005;55:368–376.
 
16. Kato Y, Hasegawa M, Numasato S, et al. Primary mucosa-associated lymphoid tissue-type lymphoma arising in the kidney. Int J Urol 2008;15:90–92.
 
17. Rosenbaum SJ, Lind T, Antoch G, Bockisch A. False-positive FDG PET uptake—the role of PET/CT. Eur Radiol 2006;16:1054–1065.
 
18. Leisure GP, Vesselle HJ, Faulhaber PF, et al. Technical improvements in fluorine-18-FDG PET imaging of the abdomen and pelvis. J Nucl Med Technol 1997;25:115–119.
 
19. Lannoo L, Smets S, Steenkiste E, et al. Intravascular large B-cell lymphoma of the uterus presenting as fever of unknown origin (FUO) and revealed by FDG-PET. Acta Clin Belg 2007;62:187–190.
 
20. Hoshino A, Kawada E, Ukita T, et al. Usefulness of FDG-PET to diagnose intravascular lymphomatosis presenting as fever of unknown origin. Am J Hematol 2004;76:236–239.
 
21. Agmon-Levin N, Berger I, Shtalrid M, et al. Primary hepatic lymphoma: a case report and review of the literature. Age Ageing 2004;33:637–640.
 
22. Venizelos ID, Rombis V, Tulupidis S, et al. Primary anaplastic large cell lymphoma of the kidney. Leuk Lymphoma 2003;44:353–355.
 
23. Tefekli A, Baykal M, Binbay M, et al. Lymphoma of the kidney: primary or initial manifestation of rapidly progressive systemic disease? Int Urol Nephrol 2006;38:775–778.
 
24. Khong PL, Pang CB, Liang R, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol 2008;87:613–621.
 
25. Karantanis D, Subramaniam RM, Peller PJ, et al. The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clin Lymphoma Myeloma 2008;8:94–99.
 
26. Nakagawa T, Yamada M, Suzuki Y. 18F-FDG uptake in reactive neck lymph nodes of oral cancer: relationship to lymphoid follicles. J Nucl Med 2008;49:1053–1059.
 
27. Zeng W, Lechowicz MJ, Winton E, et al. Spectrum of FDG PET/CT findings in Burkitt lymphoma. Clin Nucl Med 2009;34:355–358.